High dose rate endobronchial brachytherapy in the management of lung cancer: Response and toxicity evaluation in 158 patients

Simple item page
dc.contributor.authorOzkok S.
dc.contributor.authorKarakoyun-Celik O.
dc.contributor.authorGoksel T.
dc.contributor.authorMogulkoc N.
dc.contributor.authorYalman D.
dc.contributor.authorGok G.
dc.contributor.authorBolukbasi Y.
dc.date.accessioned2024-07-22T08:22:34Z
dc.date.available2024-07-22T08:22:34Z
dc.date.issued2008
dc.description.abstractThe aim of this study was to evaluate the symptomatic and endoscopic responses as well as the toxicities in 158 patients with endobronchial lung cancer treated with high dose rate endobronchial brachytherapy (HDR-EB). Forty-three patients with stage III NSCLC were treated with 60 Gy external beam radiotherapy (ERT) and three applications of 5 Gy each of HDR-EB (group A). Seventy-four patients who did not receive previous RT were treated with 30 Gy ERT and two applications of 7.5 Gy HDR-EB with palliative intent (group B). Forty-one patients with recurrent tumor who were irradiated previously were treated with three applications of 7.5 Gy HDR-EB, with palliative intent (group C). In group A, bronchoscopic complete (CR) and overall response rates (ORR) were 67% and 86%, respectively. Symptomatic improvement was obtained in 58% of patients with cough, 77% of patients with dyspnea and 100% of patients with hemoptysis. Two and 5-year survival rates were 25.5% and 9.5%, respectively and the median survival time (MST) was 11 months. In group B, the bronchoscopic CR and ORR were 39% and 77%, respectively and 28% and 72% in group C. The symptomatic response rates were 57% and 55% for cough, 90% and 78% for dyspnea and 94% and 77% for hemoptysis, with a MST of 7 and 6 months in Groups B and C, respectively. Eighteen patients (11%) died of fatal hemoptysis (FH) with the median time to this event of 7 months. Treatment intent (p < 0.001), total BED (p < 0.001) and the number of HDR-EB fractions (p < 0.001) were significant prognostic factors for FH. HDR-EB provides effective palliation in relieving the symptoms of patients with endobronchial lung cancer, however, there is a risk of developing FH that is associated with a high BED and multiple HDR-EB applications. © 2008 Elsevier Ireland Ltd. All rights reserved.
dc.identifier.DOI-ID10.1016/j.lungcan.2008.03.018
dc.identifier.issn01695002
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19141
dc.language.isoEnglish
dc.publisherElsevier Ireland Ltd
dc.subjectadult
dc.subjectaged
dc.subjectarticle
dc.subjectbrachytherapy
dc.subjectcancer patient
dc.subjectcancer risk
dc.subjectcancer staging
dc.subjectcancer survival
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjectcoughing
dc.subjectdyspnea
dc.subjectexternal beam radiotherapy
dc.subjectfemale
dc.subjecthemoptysis
dc.subjecthuman
dc.subjectlung cancer
dc.subjectmale
dc.subjectpriority journal
dc.subjectsurvival rate
dc.subjectsurvival time
dc.subjecttreatment response
dc.titleHigh dose rate endobronchial brachytherapy in the management of lung cancer: Response and toxicity evaluation in 158 patients
dc.typeArticle

Files

Collections

Scopus Koleksiyonu